blue cross blue shield glp-1 coverage 2026 plans reverse course on GLP-1 Drugs Could Raise Employer

The concern isnt that CMS is asking tough questions about demonstrations

What is included in the scope of this GLP-1 receptor agonist market report

Hymagic-4D (4D Hyaluronic acids)

E2, one of the primary ovarian sex hormones, drives cyclic proliferation of uterine epithelial cells (102)

When multiple studies addressed similar questions, priority was given to larger cohorts, prospective designs, and randomized controlled trials

These second order effects will become more far reaching as insurance coverage becomes wider for these drugs - this will be the differentiator between the risk/reward being better on the first-order beneficiaries (LLY and NVO) and the second-order plays like short bariatric surgery/sleep apnea/gyms/fast food & CPG